Emergent BioSolutions EBS today announced that the European
Commission granted orphan medicinal product designation to Emergent's
humanized single chain monoclonal antibody against CD37, also called
TRU-016, for the treatment of chronic lymphocytic leukemia (CLL).
“Receiving orphan medicinal product designation for TRU-016 from the
European Commission, following orphan drug designation from the FDA in
2011, is an important step in the development of TRU-016 and underscores
the medical need in treating B-cell malignancies like CLL,” said Scott
C. Stromatt, M.D., senior vice president and chief medical officer of
Emergent BioSolutions. “Emergent is pleased to receive these
designations and we are looking forward to data from our ongoing CLL
studies.”
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in